STOCK TITAN

NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

NeOnc Technologies Holdings (NTHI) said the FDA rescheduled the End-of-Phase 1 Type B meeting for oral NEO212 to November 23, 2026. The meeting was previously set for November 17, 2026. NeOnc plans to seek feedback on Phase 2 study design and potential regulatory pathways. The meeting schedule does not establish FDA agreement on the design or eventual drug approval.

The FDA authorized Phase 2a and Phase 2b of NEO212-01 in September 2025. Phase 1 dose escalation ended after a dose-limiting toxicity at 810 mg, and 610 mg was selected as the recommended Phase 2 dose. In Phase 1, one patient with recurrent glioblastoma had a partial response, and one with lung cancer that spread to the brain had stable disease.

Loading...
Loading translation...
4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointFDA authorization to proceed with Phase 2a and Phase 2b of NEO212-01 was granted in September 2025
  • Minor pointRecommended Phase 2 dose of 610 mg was selected after Phase 1 dose escalation
  • Minor pointPartial response in one patient with recurrent glioblastoma included approximately 60% tumor shrinkage and 21 treatment months of disease control
  • Minor pointStable disease lasting approximately 16 months was observed in one patient with lung cancer that had spread to the brain

Negative

  • Minor pointDose-limiting toxicity at 810 mg led NeOnc to stop Phase 1 dose escalation
  • Minor pointFDA meeting moved from November 17 to November 23, 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.Individual patient outcomes do not establish efficacy and require confirmation in larger studies

Key Figures

Rescheduled FDA meeting: November 23, 2026 Dose-limiting toxicity dose: 810 mg Recommended Phase 2 dose: 610 mg +3 more
Rescheduled FDA meeting
November 23, 2026
NEO212 End-of-Phase 1 Type B meeting; previously November 17, 2026
Dose-limiting toxicity dose
810 mg
Once daily on Days 1–5 of a 28-day cycle
Recommended Phase 2 dose
610 mg
NEO212-01 trial
Tumor size reduction
Approximately 60%
One patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma; partial response
Disease control duration
21 treatment months
Following the partial response in one patient
Stable disease duration
Approximately 16 months
One patient with lung cancer metastatic to the brain

Previous Clinical trial Reports

1 past event · Latest: Sep 28
Same Type 1 event
  1. Sep 28

    FDA meeting

    24h Move
    -4.5%

    Initial End-of-Phase 1 meeting date was November 17, with NEO212 Phase 2 design discussions planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

end-of-phase 1 type b meeting, dose-limiting toxicity, partial response, immune checkpoint inhibitors
4 terms
end-of-phase 1 type b meeting regulatory
"rescheduled the Company’s End-of-Phase 1 Type B meeting concerning oral NEO212"
A U.S. Food and Drug Administration (FDA) "end-of-Phase 1" Type B meeting is a formal, scheduled discussion between a drug developer and regulators held after initial human safety testing (Phase 1). It focuses on the Phase 1 results, safety issues, and the design and data expectations for the next stage of development (Phase 2), serving like a checkpoint where the regulator and sponsor agree on what evidence is needed to move forward. This matters to investors because the meeting’s outcome can clarify timelines, required studies, and regulatory risk for a drug program.
dose-limiting toxicity medical
"dose escalation was discontinued following a dose-limiting toxicity at 810 mg"
Dose-limiting toxicity is a serious, treatment-related side effect observed in clinical trials that prevents researchers from safely increasing a drug’s dose. It matters to investors because these toxic effects set the maximum tolerated dose, influence whether a drug can reach levels that are effective, and therefore affect development timelines, costs, and the chance of regulatory approval — like a safety speed limit on how far a drug program can go.
partial response medical
"treatment with NEO212 resulted in a partial response"
A partial response is a clinical outcome where a treatment produces a clear, measurable improvement in a disease — for example a substantial shrinkage of a tumor or reduction in symptom measures — but does not eliminate the disease entirely. For investors it signals meaningful efficacy that can support regulatory progress, further trials, or commercial potential, like seeing a product gain market traction even though it hasn’t achieved a complete cure.
immune checkpoint inhibitors medical
"including immune checkpoint inhibitors"
Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Meeting will address Phase 2 study design and potential regulatory pathways for oral NEO212

CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has rescheduled the Company’s End-of-Phase 1 Type B meeting concerning oral NEO212 from the previously announced date of November 17, 2026, to Monday, November 23, 2026.

At the meeting, NeOnc intends to seek FDA feedback on its NEO212 clinical development program, including the proposed patient population, trial design, endpoints and dose selection for the Phase 2 portions of the NEO212-01 trial, as well as potential regulatory pathways for NEO212. The meeting provides an opportunity for discussion; its scheduling does not establish FDA agreement on a trial design or eventual approval of NEO212.

The meeting follows completion of the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. NeOnc previously reported that dose escalation was discontinued following a dose-limiting toxicity at 810 mg, administered once daily on Days 1 through 5 of a 28-day cycle, and that 610 mg was selected as the recommended Phase 2 dose. In September 2025, FDA authorized the Company to proceed with the Phase 2a and Phase 2b portions of NEO212-01.

NeOnc has also reported encouraging clinical activity observed during the Phase 1 portion of the trial. In one patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma (GBM), treatment with NEO212 resulted in a partial response, including an approximately 60% reduction in tumor size, followed by prolonged disease control lasting 21 treatment months. In a second patient with lung cancer metastatic to the brain who had previously received and progressed following multiple lines of therapy, including immune checkpoint inhibitors, treatment with NEO212 was associated with stable disease lasting approximately 16 months. While these individual patient outcomes do not establish efficacy and require confirmation in larger studies, they provide the clinical rationale for further evaluation of NEO212 in the Phase 2 portions of the NEO212-01 trial.

“We believe the durable activity NEO212 showed in Phase 1, together with a well-defined recommended Phase 2 dose, gives us a compelling foundation for the next stage of development,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “We look forward to discussing our Phase 2 plans with the FDA as we work to advance NEO212 for patients with CNS cancers who urgently need new options.”

Management anticipates hosting an investor webinar following issuance and receipt of the FDA’s official meeting minutes to discuss the Agency’s feedback and the Company’s anticipated next steps for the NEO212 development program. The Company expects to announce the webinar date, time and registration details separately.

About NEO212

NEO212 is an investigational oral conjugate of temozolomide and NEO100. It is being studied for CNS cancers, including recurrent glioblastoma. Preclinical studies support further evaluation of its potential activity and delivery characteristics; clinical efficacy and safety have not been established. NEO212 is being developed under an FDA investigational new drug application.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated date and format of the FDA meeting, the topics to be discussed, issuance and receipt of the FDA’s official meeting minutes, the anticipated investor webinar and its timing, future clinical trial design, potential regulatory pathways, the Company’s clinical development programs and the clinical potential of NEO212. These statements reflect current expectations and involve risks and uncertainties. NEO212 is investigational and has not been approved by any regulatory authority. The scheduling of the FDA meeting does not establish FDA agreement on a development plan or eventual approval of NEO212. FDA feedback may differ from the Company’s proposals; the meeting may be rescheduled or its format changed; issuance of the FDA’s official meeting minutes may be delayed and the anticipated investor webinar may be delayed or may not occur; additional clinical, nonclinical or manufacturing work may be required; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. The individual patient outcomes described in this release do not establish efficacy and require confirmation in larger studies. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact
info@neonc.com

Investor Contact
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is NeOnc Technologies’ rescheduled FDA meeting for NEO212?

NeOnc’s End-of-Phase 1 Type B meeting for oral NEO212 is now scheduled for November 23, 2026, instead of November 17, 2026.

What Phase 2 decisions will NeOnc Technologies discuss with the FDA for NEO212?

NeOnc plans to seek feedback on who would enroll, how the trial would run, what it would measure and which dose to use in the Phase 2 portions of NEO212-01.

How was the 810 mg NEO212 dose given in NeOnc Technologies’ Phase 1 trial?

The 810 mg dose was given once daily on days 1 through 5 of a 28-day cycle.

When does NeOnc Technologies plan to update investors after its FDA meeting on NEO212?

NeOnc expects to hold an investor webinar after it receives the FDA’s official meeting minutes. The company plans to discuss FDA feedback and anticipated next steps, and expects to announce the date, time and registration details separately.

Keep reading